Errors in Number at Risk and Author Email Address

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2018.

. 2018 Nov 1;4(11):1625.

doi: 10.1001/jamaoncol.2018.5345.

No abstract available

Erratum for

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Han B, et al. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. JAMA Oncol. 2018. PMID: 30098152 Free PMC article. Clinical Trial.

1. Han B, Li K, Wang Q, et al. . Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 clinical trial [published online August 9, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.3039 - DOI - PMC - PubMed